test tube close up



Market Cap€10m

Last Close €0.21

Hybrigenics is a French biotech company. It is developing its lead drug, inecalcitol, against orphan adult leukaemias and is currently conducting an international Phase II study in acute myeloid leukaemia. The company has a research programme on USP inhibitors and an R&D collaboration with Servier focused on USP inhibitors in oncology.

More Hybrigenics content >

Investment summary

Edison Investment Research is terminating coverage on Hybrigenics (ALHYG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2016A 2.6 (3.5) (4.0) (11.2) N/A N/A
2017A 1.9 (6.8) (7.3) (17.7) N/A N/A
2018E 3.6 (3.5) (4.1) (8.7) N/A N/A
2019E 2.2 (3.3) (4.0) (7.6) N/A N/A
Content on Hybrigenics
Hybrigenics – Termination of coverage
Healthcare | research Termination | 4 January 2019
Hybrigenics – Fresh funds to expand clinical studies and R&D
Healthcare | research Update | 14 August 2018
Hybrigenics – H117 results released, business on track
Healthcare | research Non-client QV | 14 August 2018
View more
Share price graph
Balance sheet
Forecast net cash (€m) 1.5
Forecast gearing ratio (%) N/A
Price performance
Actual 122.1 (49.1) (66.9)
Relative* 125.9 (45.3) (61.6)
52-week high/low €0.7/€0.0
*% relative to local index
Key management
Alain Muňoz Chairman
Rémi Delansorne CEO
Guillaume Floch CFO